 Home > Active Ingredient News > Drugs Articles > Expanding the immunotherapy pipeline, Baiming Xinkang acquires Aptope assets

Expanding the immunotherapy pipeline, Baiming Xinkang acquires Aptope assets

 Last Update: 2021-09-13
 Source: Internet
 Author: User

Tags

drug field test

fasenra mechanism action

shenzhen technology co ltd

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Expand the immunotherapy pipeline to provide a new treatment plan for a series of autoimmune diseases

Hangzhou, China and Dipenbeck, Belgium (August 18, 2021): Biomax Biotech (Hangzhou) Co.

Apitope uses its unique technology platform to develop new antigen-specific immunotherapies for a variety of autoimmune diseases

"The Apitope assets we are going to acquire have a good overlap and synergy with our business in the field of allergy immunotherapy, which is very in line with Worg's business strategy

Dr.

Apitope Chairman Stéphane Verdood and CEO Hayley French commented: “We are very pleased to work with Worg to promote the further development of Apitope immunotherapy and provide patients with novel, safe and effective treatments

About Baiming Xinkang

Worg is a professional biopharmaceutical company focusing on the research and development of innovative immunotherapies, striving to meet medical needs in the field of allergies and related diseases

About Apitope

Apitope is a clinical stage biotechnology company focusing on the development of antigen-specific immunotherapies for autoimmune diseases

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Velpatasvir CAS 1377049-84-7

CAS No.: 1377049-84-7

Pharmacy Grade

$88-98/KG FOB

High purity Velpatasvir 98% with best price 1377049-84-7 and Velpatasvir raw material

CAS No.: 1377049-84-7

Pharmacy Grade

$8.8-10/MT FOB

1,2,4-Triazole-3-Carboxylic Acid Methylester

CAS No.: 4928-88-5

Different Grade

$0.1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.